Magnitude of QT prolongation associated with a higher risk of Torsades de Pointes

Pharmacoepidemiology and Drug Safety

Volumn 18, Issue 3, 2009, Pages 235-239

  Lin, Yeong Liang ^a   Kung, Mei Fen ^a  

^a Center for Drug Evaluation   (Taiwan)

Author keywords

Cut off value; QT prolongation; Torsades de Pointes

Indexed keywords

AMITRIPTYLINE; ARSENIC TRIOXIDE; ASTEMIZOLE; CHLOROQUINE; CISAPRIDE; CLARITHROMYCIN; DESIPRAMINE; DROPERIDOL; ERYTHROMYCIN; GATIFLOXACIN; HALOFANTRINE; HALOPERIDOL; MESORIDAZINE; METHADONE; MOXIFLOXACIN; OLANZAPINE; PAROXETINE; PENTAMIDINE; PIMOZIDE; QUETIAPINE; RISPERIDONE; RITONAVIR; SPARFLOXACIN; TELITHROMYCIN; TERFENADINE; THIORIDAZINE; UNINDEXED DRUG; VARDENAFIL; VENLAFAXINE; ZIPRASIDONE; DRUG;

ARTICLE; COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; DISEASE ASSOCIATION; DISEASE SEVERITY; DRUG DOSE TITRATION; HUMAN; MAJOR CLINICAL STUDY; MONOTHERAPY; PRIORITY JOURNAL; QT INTERVAL; QT PROLONGATION; RISK ASSESSMENT; TORSADE DES POINTES; CHEMICALLY INDUCED DISORDER; LONG QT SYNDROME; METHODOLOGY; PATHOPHYSIOLOGY; POSTMARKETING SURVEILLANCE; RISK FACTOR;

HUMANS; LONG QT SYNDROME; PHARMACEUTICAL PREPARATIONS; PRODUCT SURVEILLANCE, POSTMARKETING; RISK ASSESSMENT; RISK FACTORS; TORSADES DE POINTES;

EID: 65249171011     PISSN: 10538569     EISSN: 10991557     Source Type: Journal    
DOI: 10.1002/pds.1707     Document Type: Article

References (39)

1. Haverkamp W, Breithardt G, Camm AJ, et al. The potential for QT prolongation and proarrhythmia by non-arrhythmic drugs: clinical and regulatory implications: report on a policy conference of the European Society of Cardiology. Eur Heart J 2000; 21: 1216-1231.
2. Anderson ME, Al Khatib SM, Roden DM, et al. Cardiac repolarization: current knowledge, critical gaps and new approaches to drug development and patient management. Am Heart J 2002; 144: 769-781.
3. International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use. ICH Harmonised Tripartite Guideline: The Clinical Evaluation of QT/QTc Interval Prolongation and Proarrhythmic Potential for Non-antiarrhythmic Drugs. Geneva, Switzerland: International Conference on Harmonisation, 2005.
4. International Conference of Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use. ICH Harmonised Tripartite Guideline: The Nonclinical Evaluation of the Potential for Delayed Ventricular Repolarization (QT Interval Prolongation) by Human Pharmaceuticals. Geneva, Switzerland: International Conference on Harmonisation, 2005.
5. Roden DM. Drug-induced prolongation of the QT interval. N Eng J Med 2004; 350: 1013-1022.
6. Lin YL, Chan K. Pharmacokinetic and pharmacodynamic characterization of Non-antiarrhythmic QT-prolonging drugs associated with Torsades de Pointes. Drug Inf J 2008; 42: 211-219.
7. FDA. DrugsΦDA. FDA CDER, Rockville. http://www.accessdata.fda.gov/ scripts/cder/drugsatfda [accessed 28 August 2008].
8. European Medicines Agency. Authorized medicinal products for human use. http://www.emea.europa.eu/htms/human/epar/eparintro.htm [accessed 28 August 2008].
9. Zweig MH, Campbell G. Receiver operating characteristic (ROC) plots: a fundamental evaluation tool in clinical medicine. Clin Chem 1993; 39: 561-577.
10. Honig PK, Wortham DC, Zamani K, et al. Terfenadine-ketoconazole interaction. Pharmacokinetic and electrocardiographic consequences. JAMA 1993; 269: 1513-1518.
11. Khongphatthanayothin A, Lane J, Thomas D, et al. Effects of cisapride on QT interval in children. J Pediatr 1998(133): 51-56.
12. Charbit B, Albaladejo P, Funck-Brentano C, et al. Prolongation of QTc interval after postoperative nausea and vomiting treatment by droperidol or ondansetron. Anesthesiology 2005; 102: 1094-1100.
13. Zhou J, Meng R, Li X, et al. The effect of arsenic trioxide on QT interval prolongation during APL therapy. Chin Med J 2003; 116: 1764-1766.
14. Harrigan EP, Miceli JJ, Anziano R, et al. A randomized evaluation of the effects of six antipsychotic agents on QTc, in the absence and presence of metabolic inhibition. J Clin Psychopharmacol 2004; 24: 62-69.
15. Girgis I, Gualberti J, Langan L, et al. A prospective study of the effect of iv pentamidine therapy on ventricular arrhythmias and QTc prolongation in HIV-infected patients. Chest 1997; 112: 646-652.
16. Mzayek F, Deng H, Mather FJ, et al. Randomized dose-ranging controlled trial of AQ-13, a candidate antimalarial and chloroquine in healthy volunteers. PLoS Clin Trials 2007; 2: e6.
17. Fulop G, Phillips RA, Shapiro AK, et al. ECG changes during haloperidol and pimozide treatment of Tourette's disorder. Am J Psychiatry 1987; 144: 673-675.
18. Charbit B, Becquemont L, Lepere B, et al. Pharmacokinetic and pharmacodynamic interaction between grapefruit juice and halofantrine. Clin Pharmacol Ther 2002; 72: 514-523.
19. Kornick CA, Kilborn MJ, Santiago-Palma J, et al. QTc interval prolongation associated with intravenous methadone. Pain 2003; 105: 499-506.
20. DeAbate CA, Henry D, Bensch G, et al. Sparfloxacin vs ofloxacin in the treatment of acute bacterial exacerbations of chronic bronchitis. A multicenter, double-blind, randomized, comparative study. Chest 1998; 114: 120-130.
21. Salih ISM, Thanacoody RHK, McKay GA, et al. Comparison of the effects of thioridazine and mesoridazine on the QT interval in healthy adults after single oral doses. Clin Pharmacol Ther 2007; 82: 549-554.
22. Delgado LF, Pferferman A, Sole D, et al. Evaluation of the potential cardiotoxicity of the antihistamines terfenadine, astemizole, loratadine and cetirizine in atopic children. Ann Allergy Asthma Immunol 1998; 80: 333-337.
23. Morganroth J, DiMarco JP, Anzueto A, et al. A randomized trial comparing the cardiac rhythm safety of moxifloxacin vs levofloxacin in elderly patients hospitalized with community acquired pneumonia. Chest 2005; 128: 3398-3406.
24. FDA. Review of Tequin. FDA CDER, Rockville; 2002. http://www.fda.gov/cder/foi/nda/2002/021061s010_s016_Tequin_MedR.pdf [accessed 28 August 2008].
25. Mishra A, Friedman HS, Sinha AK. The effects of erythromycin on the electrocardiogram. Chest 1999; 115: 983-986.
26. van Haarst AD, van't Klooster GA, van Gerven JM, et al. The influence of cisapride and clarithromycin on QT intervals in healthy volunteers. Clin Pharmacol Ther 1998; 64: 542-546.
27. Demolis JL, Vacheron F, Cardus S, et al. Effect of single and repeated oral doses of telithromycin on cardiac QT interval in healthy subjects. Clin Pharmacol Ther 2003; 73: 242-252.
28. Levitra. Physician's Desk Reference, (61th edn), Thomson PDR: Montvale, NJ, 2007; 3034-3038.
29. Effexor. Physician's Desk Reference, (61th edn), Thomson PDR: Montvale, NJ, 2007; 3411-3417.
30. Krulewicz S, Carpenter D, Fong R, et al. Analysis of electrocardiographic data following use of paroxetine in pediatric depression and obsessive-compulsive disorder. J Am Acad Child Adolesc Psychiatry 2006; 45: 422-430.
31. Sarapa N, Nickens DJ, Raber SR, et al. Ritonavir 100 mg does not cause QTc prolongation in healthy subjects: a possible role as CYP 3A inhibitor in thorough QTc studies. Clin Pharmacol Ther 2008; 83: 152-159.
32. Leonard HL, Meyer MC, Swedo SE, et al. Electrocardiographic changes during desipramine and clomipramine treatment in children and adolescents. J Am Acad Child Adolesc Psychiatry 1995; 34: 1460-1468.
33. Claghorn JL, Schroeder J, Goldstein BJ, et al. Comparison of the electrocardiographic effect of dothiepin and amitriptyline. J Clin Psychiatry 1984; 45: 291-293.
34. Dujovne CA, Atkins F, Wong B, et al. Electrocardiographic effects of probucol. A controlled prospective clinical trial. Eur J Clin Pharmacol 1984; 26: 735-739.
35. Haddad PM, Anderson IM. Antipsychotic-related QTc prolongation, torsade de pointes and sudden death. Drugs 2002; 62: 1649-1671.
36. Moss AJ. Measurement of the QT interval and the risk associated with QTc interval prolongation: a review. Am J Cardiol 1993; 72: 23B-25B.
37. Welch R, Chue P. Antipsychotic agents and QT changes. J Psychiatry Neurosci 2000; 25: 154-160.
38. Shah RR. The significance of QT interval in drug development. Br J Clin Pharmacol 2002; 54: 188-202.
39. Dana G, Descatoire V, Pessayre D. Self-induction by erythromycin of its own biotransformation into a metabolite forming an inactive complex with reduced cytochrome P450. J Pharmacol Exp Ther 1981; 218: 509-515.